ArticleInternational journal of molecular sciences2026
A Comparative Analysis of iPSC, MSC, and 293T-Derived Exosomes for Parkinson's Disease Therapy.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Parkinson's disease (PD) lacks effective therapeutic methods. Exosomes are specialized vesicles that feature a double-layered lipid structure and are rich in proteins, miRNA, mRNA, growth factors, and other biomolecules. Their diverse components enable tissue repair and cell activation, making exosomes a promising candidate for therapeutic applications, including for PD. Exosomes are widely studied in cancer treatment and regenerative medicine. Since these vesicles retain the characteristics of their source cells, selecting the appropriate cell type is crucial. In this study, we compared exosomes derived from induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and 293T cells in terms of particle production, protein content, cellular uptake efficiency, and therapeutic effects on PD. The results showed that exosomes derived from iPSCs outperformed those from the other two cell types in all evaluated aspects, followed by MSC-derived exosomes, while 293T-derived exosomes were the least effective. This study provides valuable comparative data to inform the selection of source cells for exosome-based therapies in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.